S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
NASDAQ:ABMD

Abiomed Stock Forecast, Price & News

$350.36
-0.25 (-0.07 %)
(As of 09/24/2021 04:00 PM ET)
Add
Compare
Today's Range
$345.26
$352.02
50-Day Range
$314.62
$376.20
52-Week Range
$242.73
$387.40
Volume193,829 shs
Average Volume267,838 shs
Market Capitalization$15.90 billion
P/E Ratio104.27
Dividend YieldN/A
Beta1.31
30 days | 90 days | 365 days | Advanced Chart
Receive ABMD News and Ratings via Email

Sign-up to receive the latest news and ratings for Abiomed and its competitors with MarketBeat's FREE daily newsletter.


Abiomed logo

About Abiomed

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded by David M. Lederman in 1981 and is headquartered in Danvers, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.01 out of 5 stars

Medical Sector

561st out of 1,351 stocks

Surgical & Medical Instruments Industry

58th out of 123 stocks

Analyst Opinion: 1.1Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Abiomed (NASDAQ:ABMD) Frequently Asked Questions

Is Abiomed a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abiomed in the last twelve months. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Abiomed stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABMD, but not buy additional shares or sell existing shares.
View analyst ratings for Abiomed
or view top-rated stocks.

What stocks does MarketBeat like better than Abiomed?

Wall Street analysts have given Abiomed a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Abiomed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Abiomed's next earnings date?

Abiomed is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Abiomed
.

How were Abiomed's earnings last quarter?

Abiomed, Inc. (NASDAQ:ABMD) released its earnings results on Tuesday, August, 3rd. The medical equipment provider reported $1.41 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.06 by $0.35. The medical equipment provider earned $252.59 million during the quarter, compared to the consensus estimate of $243.81 million. Abiomed had a net margin of 16.51% and a trailing twelve-month return on equity of 16.35%.
View Abiomed's earnings history
.

How has Abiomed's stock been impacted by Coronavirus (COVID-19)?

Abiomed's stock was trading at $151.13 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABMD stock has increased by 131.8% and is now trading at $350.36.
View which stocks have been most impacted by COVID-19
.

What guidance has Abiomed issued on next quarter's earnings?

Abiomed issued an update on its FY 2022 earnings guidance on Wednesday, September, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.03 billion-$1.05 billion, compared to the consensus revenue estimate of $1.02 billion.

What price target have analysts set for ABMD?

4 analysts have issued 12 month target prices for Abiomed's shares. Their forecasts range from $245.00 to $425.00. On average, they anticipate Abiomed's share price to reach $363.75 in the next twelve months. This suggests a possible upside of 3.8% from the stock's current price.
View analysts' price targets for Abiomed
or view top-rated stocks among Wall Street analysts.

Who are Abiomed's key executives?

Abiomed's management team includes the following people:
  • Michael R. Minogue, Chairman, President & Chief Executive Officer (LinkedIn Profile)
  • David M. Weber, Chief Operating Officer & Senior Vice President
  • Todd A. Trapp, Chief Financial Officer & Vice President
  • Thorsten Sieß, Chief Technology Officer & Vice President
  • Charles A. Simonton, Chief Medical Officer

What is Michael R. Minogue's approval rating as Abiomed's CEO?

96 employees have rated Abiomed CEO Michael R. Minogue on Glassdoor.com. Michael R. Minogue has an approval rating of 72% among Abiomed's employees.

What other stocks do shareholders of Abiomed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abiomed investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Intuitive Surgical (ISRG), Square (SQ), Netflix (NFLX), Adobe (ADBE) and salesforce.com (CRM).

What is Abiomed's stock symbol?

Abiomed trades on the NASDAQ under the ticker symbol "ABMD."

Who are Abiomed's major shareholders?

Abiomed's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.75%), BlackRock Inc. (9.24%), Baillie Gifford & Co. (8.01%), State Street Corp (4.31%), Primecap Management Co. CA (4.09%) and Renaissance Technologies LLC (3.70%). Company insiders that own Abiomed stock include Andrew J Greenfield, Dorothy E Puhy, Joseph Riccelli, Magdalena Yesil, Martin P Sutter, Michael R Minogue, Michael R Minogue and Paul Thomas.
View institutional ownership trends for Abiomed
.

Which major investors are selling Abiomed stock?

ABMD stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Jackson Square Partners LLC, Renaissance Technologies LLC, Wells Fargo & Company MN, Primecap Management Co. CA, Brown Capital Management LLC, Jupiter Asset Management Ltd., and Villere ST Denis J & Co. LLC. Company insiders that have sold Abiomed company stock in the last year include Andrew J Greenfield, Joseph Riccelli, Magdalena Yesil, Martin P Sutter, Michael R Minogue, and Paul Thomas.
View insider buying and selling activity for Abiomed
or view top insider-selling stocks.

Which major investors are buying Abiomed stock?

ABMD stock was bought by a variety of institutional investors in the last quarter, including Ownership Capital B.V., Macquarie Group Ltd., Baillie Gifford & Co., Amundi, Vanguard Group Inc., Legal & General Group Plc, UBS Asset Management Americas Inc., and Marathon Asset Management LLP.
View insider buying and selling activity for Abiomed
or or view top insider-buying stocks.

How do I buy shares of Abiomed?

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abiomed's stock price today?

One share of ABMD stock can currently be purchased for approximately $350.36.

How much money does Abiomed make?

Abiomed has a market capitalization of $15.90 billion and generates $847.52 million in revenue each year. The medical equipment provider earns $225.52 million in net income (profit) each year or $4.94 on an earnings per share basis.

How many employees does Abiomed have?

Abiomed employs 1,725 workers across the globe.

Does Abiomed have any subsidiaries?

The following companies are subsidiares of Abiomed: ABD Holding Company, ABIOMED Athlone Ltd, ABIOMED Australia Pte. Ltd, ABIOMED Europe, ABIOMED Japan KK, ABIOMED Limited, ABIOMED R&D, ABIOMED SARL, ABIOMED Singapore Pte. Ltd, AIS GmbH Aachen Innovative Solutions, ECP Entwicklungsgesellschaft mbH, and Impella Cardiosystems.

When was Abiomed founded?

Abiomed was founded in 1981.

What is Abiomed's official website?

The official website for Abiomed is www.abiomed.com.

Where are Abiomed's headquarters?

Abiomed is headquartered at 22 CHERRY HILL DR, DANVERS MA, 01923.

How can I contact Abiomed?

Abiomed's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at (978) 646-1400 or via email at [email protected].


This page was last updated on 9/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.